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Abstract 
Background. Dinucleoside polyphosphates (NpnN) have patho-physiologic roles in 
cardiovascular disease and are newly detected uremic retention solutes. They were retrieved 
in human plasma, tissues and cells. Although their impact on several cell systems involved in 
vascular damage (endothelium, smooth muscle cells and thrombocytes) has been evaluated, 
their effect on different types of leukocytes has never been studied. 
Methods. This study evaluates, for the first time, the impact of NpnN on monocyte, 
granulocyte and lymphocyte oxidative burst activity at baseline and after stimulation with 
fMLP and PMA in whole blood. Ap3A to Ap6A were tested to investigate the effect of the 
number of phosphate groups on ROS production. The effect of the type of nucleoside was 
evaluated by comparing Ap4G, Gp4G, Up4A and Ap4A. 
Results. This study demonstrated that especially lymphocytes are susceptible to ApnA. 
Depending on phosphate chain length different effects were observed. At baseline and with 
fMLP, Ap4A, Ap5A and Ap6A enhanced lymphocyte free radical production. In addition, 
Ap3A, Ap4A and Ap5A increased PMA-stimulated ROS production in lymphocytes. 
Monocytes and granulocytes parallel the lymphocyte response albeit with an inhibition of 
Ap6A on granulocytes. Considering NpnN with four phosphate groups, Up4A showed the most 
important stimulatory effects on monocytes and Ap4A on lymphocytes. 
Conclusions. NpnN mainly have a leukocyte activating impact, most significant for Ap4A, 
considering phosphate chain length, and for Up4A, considering the type of nucleosides. These 
results suggest that pro-inflammatory effects of NpnN can contribute to the development of 
atherosclerosis, probably in the early stages of chronic kidney disease but their chemical 
composition affects their activity. 
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Short summary: The dinucleoside polyphosphates, a group of newly identified uremic 
retention solutes, were tested on the leukocyte oxidative burst activity. Both the effect of the 
number of phosphate groups as well as the type of nucleosides were evaluated. Up4A and 
Ap4A were considered the most important molecules in monocytes and lymphocytes and thus 
can contribute to the vascular damage seen in CKD. 
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Introduction 
In chronic kidney disease (CKD), the risk for premature death, primarily as a result of 
cardiovascular disease (CVD), is high and this risk increases early on in kidney failure [1,2]. 
Traditional risk factors insufficiently predict cardiovascular outcome in CKD; less traditional 
risk factors, like inflammation, endothelial dysfunction, oxidative stress, vascular calcification 
and malnutrition, seem to play an at least as important role [3-6]. 
When renal function deteriorates, a number of substances, normally excreted in the urine, are 
retained within the body. In 2003 a list of 90 known uremic compounds was published and 
several of these have the potential to induce vascular damage [7]. However, further 
identification of unknown compounds and the elucidation of pathophysiological mechanisms 
remains necessary to better understand the process of vessel damage in CKD and to develop 
specific therapeutic interventions [8-10]. 
The dinucleoside polyphosphates (NpnN) are a newly identified group of compounds only 
recently added to the list of uremic retention solutes [11]. NpnN contain two nucleosides 
interconnected by a variable number of phosphates; with a molecular weight between 800 and 
1200 Dalton, they belong to the so-called “middle molecules” (molecular structures: see 
Figure 1) [12]. 
Specific members of this group have been detected in human plasma, platelets, neuronal cells, 
endothelial cells, adrenal glands and myocardial tissue [13-16]. In hemodialysis patients, the 
intracellular diadenosine polyphosphates (ApnA) are increased in platelets and released upon 
activation [17]. Also renal tubular cells release Ap5A and Ap6A and uridine tetraphosphate 
(Up4A) and Up4A is released by the endothelium as well [18]. 
The NpnN play a role in vasoregulation, neurotransmission and cell signalling [19-21]. 
Related to the cardiovascular system, NpnN have been shown to interfere with the function of 
thrombocytes, endothelium and smooth muscle cells (SMC) [16,19,22-24]. Despite the fact 
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that leukocytes are also key mediators in vessel damage, studies of NpnN with these cells are 
scarce and fragmentary, both regarding the type of cell and the NpnN variant. Leukocytes play 
an important role in the immune response. CKD is considered as a state of chronic 
inflammation characterized by a dual immune response; on the one hand, many CKD patients 
have a baseline status of inflammation, while on the other hand, their immune function upon 
stimulation is often suppressed, resulting in an increased susceptibility to infection [5,25]. 
The present study investigates the biological impact of a series of NpnN on leukocyte function 
to evaluate their contribution to the uremic syndrome. Chronic inflammation in CKD is 
associated with oxidative stress and since leukocytes are an important source of reactive 
oxygen species (ROS) [26,27] the effect of the NpnN was evaluated by measuring changes in 
leukocyte oxidative burst activity. The effect of the number of phosphate groups on leukocyte 
oxidative burst activity was studied by testing Ap3A to Ap6A, the subgroup of NpnN on which 
the most extensive information is available. Since the most pronounced effects in this analysis 
were found for Ap4A and in view of the recently demonstrated important vasoconstrictive 
effects of Up4A [18], a second series of experiments was performed concentrating on known 
NpnN with 4 phosphate groups but a varying type of nucleoside i.e. Ap4A, adenosine 
guanosine tetraphosphate (Ap4G), diguanosine tetraphosphate (Gp4G) and Up4A. Finally, the 
effect of a combination of Ap4A and Up4A was tested. 
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Materials and Methods 
Reagents 
High pressure liquid chromatography (HPLC) water (gradient grade) and acetonitrile (ACN) 
were purchased from Merck (Germany); all other substances were obtained from Sigma-
Aldrich (Germany), unless otherwise specified. 
 
Synthesis of NpnN 
The NpnN tested in vitro were Ap3A, Ap4A, Ap5A, Ap6A, Ap4G, Gp4G and Up4A. They were 
all synthesized following a protocol described by Ng and Orgel [28] and chromatographed 
according to a method by Jankowski et al. [29]. 
Briefly, depending on the type of NpnN, adenosine 5′-polyphosphates, guanosine 5′-
polyphosphates and/or uridine 5’-monophosphate were dissolved in water together with N-[2-
hydroxyethyl]-piperazine-N′-2-ethanesulfonic acid, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide, and MgCl2 and incubated at 37°C for 48 hours at pH 6.5. 
Dinucleoside polyphosphates were concentrated on a C18 reversed-phase column 
(Supersphere 100 C18 endcapped, 100 x 2; 1mm, 4 µm, 10 nm, Merck, Germany) using 40 
mM aqueous triethylammonium acetate (TEAA) and were eluted with 30% acetonitrile in 
water. The lyophilized concentrate of the reversed-phase column was injected on two C18 
reversed-phase columns connected in series (Supersphere, 300 x 8 mm, 4 µm, Merck, 
Germany) and was chromatographed in the displacement mode by use of n-butanol (100 
mM). The fractions containing NpnN of the displacement-chromatography were lyophilized 
and each fraction was chromatographed with an anion-exchange column (column:UnoQ 
(Biorad), 100 x 10 µm, 10 µm, eluent A: 20 mM K2HPO4; eluent B: 20 mM K2HPO4 and 1 M 
NaCl; gradient: 0–10 min: 0-5% B; 10–115 min: 5–40% B; and 115–120 min: 40–100% B; 
flow rate: 1:0 ml/min; and UV absorption wavelength: 254 nm). The fractions of the anion-
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exchange chromatography were desalted by HPLC reversed-phase C18 chromatography. The 
chromatographically isolated NpnN were lyophilized and stored at -20°C [29]. 
 
Sample collection 
The present protocol was approved by the local Ethics Committee after informed consent. 
Heparinized whole blood from healthy donors, not smoking and not taking any medication, 
was collected. Additionally, heparinized whole blood was taken from hemodialysis patients 
prior to the dialysis session. 
 
In vitro effect of dinucleoside polyphosphates on the leukocyte oxidative burst  
Experimental set-up 
The present study was performed according to a standardized protocol for in vitro testing of 
uremic retention solutes described by Cohen et al. [30], generated after ample discussion 
among the experts of the European Uremic Toxin Work Group (EUTox). This monograph 
recommends to test the highest reported uremic concentration. It is of note however that 
current data on NpnN concentrations are still limited. Up till now, only Jankowski et al. 
described an increased intracellular amount of ApnA in platelets and an increased release by 
platelets of hemodialysis patients upon activation. A maximum release of 154 ± 59 fg 
Ap4A/platelet (range from 95 to 213 fg Ap4A/platelet) was described [17] and since whole 
blood contains 4 x 105 platelets/µl we calculated a mean local concentration of 61.6 ng 
Ap4A/µl blood (range: 38.0 to 85.2 ng Ap4A/µl blood) or 72.2 µM (range: 45.4 to 101.9 µM). 
In the in vitro set-up therefore a concentration of 100 µM was tested for each NpnN which, 
based upon the current knowledge, rather reflects local concentrations of NpnN after release 
from their storage cells than their plasma concentration. These values also correspond to the 
local concentrations reported by Ogilvie [31]. 
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The lyophilized NpnN were resuspended separately in saline (0.9% NaCl, Baxter) in a 10 
times concentrated stock solution of 1 mM and stored at -20°C and upon testing they were 
diluted 1:10 in heparinized whole blood. 
Oxidative burst 
To evaluate the effect of the NpnN on the production of reactive oxygen species (ROS) in 
leukocytes, the Bursttest (Phagoburst®) (Orpegen Pharma, Heidelberg, Germany) was 
applied, after a 10 minute incubation period at 37°C in the presence of the separate NpnN, as 
described previously [32]. 
The oxidative burst activity of the leukocytes was measured at baseline, after moderate 
stimulation with N-formyl-Methionine-Leucine-Phenylalanine (fMLP, 0.83 µM) and after 
strong stimulation with Phorbol-12-Myristate-13-Acetate (PMA, 1.35 µM). Samples were 
analyzed with the FACScan® flow cytometer (Becton Dickinson). Experiments were repeated 
8 (ApnA) or 6 (Np4N) times. 
FACScan Analysis 
Using the CellQuest Pro™software, 10,000 events were counted in every sample. Based on 
their light scatter properties monocytes, granulocytes and lymphocytes were gated separately. 
Within these gates the percentage of rhodamine-positive cells (%) was evaluated for the 
baseline and fMLP stimulated samples. The mean fluorescence intensity (MFI) per cell was 
considered as a measure for the oxidative burst activity after PMA stimulation. 
 
Endotoxin concentration 
To exclude that an effect due to lipopolysaccharide (LPS) contamination was observed, all 
experimental solutions causing a stimulation of the oxidative burst were checked by means of 
the Limulus Amebocyte Lysate (LAL) QCL-1000-test; a quantitative kinetic and 
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chromogenic assay (Cambrex Bio Science, Walkersville, MD, USA). The detection limit of 
this assay is 0.005 endotoxin units (EU)/ml. 
 
Statistical analysis 
Data are expressed as mean ± SEM. Normality was checked with the Kolmogorov Smirnov –
test in combination with descriptive statistics. Statistics were performed using a paired t-test 
for the in vitro data. A P-value of < 0.05 was considered significant. 
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Results 
Effect of a varying number of phosphate groups on the leukocyte oxidative burst activity 
Effects of NpnN with a varying number of phosphate groups linking the two nucleoside 
moieties are described. To evaluate whether the number of phosphate groups plays a role in 
the effect of the NpnN on leukocyte oxidative burst activity, four ApnA with 3 to 6 phosphate 
groups, were tested.  
At baseline, 4.65 ± 0.10 % of the monocytes, 4.76 ± 0.07 % of the granulocytes and 2.63 ± 
0.53 of the lymphocytes (n = 8) produced ROS. As presented in Figure 2A, incubation with 
Ap4A and Ap5A induced a significant rise (P < 0.05, n = 8) in free radical production in all 
three leukocyte types. For both monocytes and lymphocytes also Ap6A resulted in a 
significantly increased percentage of rhodamine positive cells. Finally, for Ap3A no 
significant effects were observed. 
A moderate stimulation of the bursttest with fMLP resulted in a significant increase of the 
ROS production for monocytes and granulocytes, in the saline condition as well as in the 
presence of ApnA. However, only Ap6A affected the fMLP induced ROS production in 
comparison to the saline condition in monocytes. The oxidative burst in lymphocytes 
remained unaffected by fMLP as previously demonstrated and the ApnA showed an enhanced 
activity versus saline which was comparable with effects observed in baseline cells (Figure 
2B) [33]. 
After stimulation with PMA, 97.1 ± 1.51 % of the leukocytes produce ROS and therefore the 
MFI was evaluated for these samples. As demonstrated in Figure 2C, Ap4A further enhanced 
the oxidative burst activity in monocytes, while Ap6A inhibited it in granulocytes. The most 
significant effects were seen in the lymphocytes, where Ap3A, Ap4A and Ap5A significantly 
enhanced free radical production. 
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The present data demonstrate that depending on the number of phosphate groups and the type 
of leukocyte, ApnA have a different impact on the oxidative burst activity at baseline and after 
stimulation. In general, they have a leukocyte activating impact even in combination with 
another activator. This effect is most prominent in lymphocytes. 
 
Effect of varying the type of nucleoside 
Based on the previous results, the number of phosphate groups was maintained constant at 4 
in the second series of experiments, and the effect of the type of nucleosides on the oxidative 
burst response was studied by testing Ap4A, Ap4G, Gp4G and Up4A. 
Figure 3A represents the oxidative burst activity at baseline (A) for monocytes, granulocytes 
and lymphocytes. Compared to Ap4A, which was stimulatory for all cell types, for Ap4G and 
Up4A a stimulatory effect was observed in monocytes while Ap4G and Gp4G both inhibited 
the ROS production in granulocytes.  
The monocytic fMLP stimulated oxidative burst activity was enhanced in the presence of 
Up4A, while no effects on the fMLP stimulated bursttest in granulocytes were seen. None of 
the compounds with 4 phosphate groups, except for Ap4A, showed an effect on lymphocytes, 
neither at baseline nor after fMLP stimulation (Figure 3B). 
As shown in Figure 3C, Up4A caused, in parallel with Ap4A, a significant rise in free radical 
production in PMA stimulated monocytes and lymphocytes. No effect was seen on the PMA-
stimulated granulocytes or after incubation with Ap4G and Gp4G. 
By studying the effect of different types of nucleosides (Np4N), it can be concluded that again 
different effects are observed in the different types of leukocytes under study. The most 
important effects are observed in the presence of Up4A, especially in monocytes and with 
Ap4A in lymphocytes. However, after PMA stimulation Up4A induces a significantly higher 
response compared to Ap4A in both cell types. 
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Effect of the combination Ap4A and Up4A 
Because of their most prominent effects, the effect on leukocyte ROS production of a 
combination of Ap4A and Up4A was evaluated (each at 100µM). Although the above 
described results were confirmed in blood from healthy donors, no cumulative effect of the 
compounds could be demonstrated (data not shown). 
In contrast, when the Ap4A and Up4A mixture was added to whole blood obtained from 
hemodialysis patients, collected just before start of hemodialysis, no significant effects on the 
ROS production could be observed (data not shown). 
Endotoxin concentration 
All solutions tested were checked for their endotoxin concentration by performing the LAL-
test. None of them had a LPS concentration above 0.05 endotoxin units (EU)/ml, which 
corresponds to 4 pg LPS/ml, except for Ap6A containing 0.26 EU/ml.  
When testing LPS in the bursttest at this concentration, no effect was observed however. 
Therefore, it can be excluded that the effects observed are attributable to endotoxin 
contamination. 
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Discussion 
The present study evaluated the role of the NpnN as newly identified uremic retention solutes 
in CKD related inflammation and atherogenesis. To the best of our knowledge, it is the first 
time that the impact of different NpnN on oxidative burst activity of several types of 
leukocytes was tested, at baseline as well as after stimulation. The effect of the number of 
phosphate groups was studied in the most studied subgroup of dinucleoside polyphosphates, 
the ApnA (n = 3 to 6). Based upon the results the effect of the type of nucleoside was studied 
on NpnN with 4 phosphate groups but a varying type of nucleoside, i.e. Ap4A, Ap4G, Gp4G, 
Up4A. Also the effect of a combination of Ap4A and Up4A was tested. 
Mainly a pro-inflammatory effect of the NpnN on leukocytes was found. Depending on the 
number of phosphate groups, especially lymphocytes were susceptible to the ApnA, with 
Ap4A inducing a marked stimulation of the oxidative burst activity in cells at baseline, but 
also after fMLP and after PMA stimulation (Figure 2). Considering the type of nucleoside, 
Up4A was shown to exert the most significant stimulatory effects on the basal and fMLP-
activated monocytes (Figure 3A and B) and after PMA stimulation in both monocytes and 
lymphocytes (Figure 3C). A combination of both Ap4A and Up4A revealed a comparable, but 
no cumulative effect on ROS production by normal leukocytes, whereas on uremic leukocytes 
no effect on ROS production could be observed. 
Oxidative stress plays an important negative role in the cardiovascular outcome of the CKD 
patient and oxidative stress is present already in the early stages of CKD [27,34]. The present 
study learns that NpnN, especially the ones containing 4 phosphate groups, may contribute to 
this pro-inflammatory status. 
Also the type of nucleoside can be at the origin of diverse effects, as is described for 
vasoconstriction of arteries where one adenine seemed crucial and sufficient because of the 
equipotent effect of ApnA and ApnG, whereas in contrast GpnG were inactive [24]. In the 
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present study it was shown that the presences of adenosines and uridines have a stimulatory 
effect on lymphocytes and monocytes, whereas guanosines have an inhibitory effect on 
granulocytes.  
The observation that an increase of NpnN in an extreme uremic milieu does not induce 
additional ROS production by uremic leukocytes as was observed for normal leukocytes, 
leads to the assumption that the effects observed with healthy donor blood mirrors the 
importance of their effect in the early stages of CKD playing a role in the initial phase of the 
atherosclerotic process. 
The observed inhibitory effect in the presence of Ap6A and the G-containing NpnN, can be 
related to the enhanced susceptibility of the CKD patient for infection [25]. Opposite effects 
related to the phosphate chain length in the NpnN have already been demonstrated previously 
in vasoactivity or platelet aggregation [24,35]. 
The specificity of the nucleosides for the different leukocyte subpopulations is most probably 
due to variability in their purinergic P2 receptor expression patterns for NpnN. There are two 
main families of P2 receptors, P2X and P2Y. P2X receptors form plasma membrane channels 
selective for monovalent and divalent ions and do not require intracellular messengers. P2Y, 
on the other hand are G-protein coupled receptors and upon activation inositol 1,4,5-
triphosphate is generated and intracellular Ca2+ is released, followed by a Ca2+ influx from 
outside the cell [36]. Each of these receptors has a series of subtypes and as recently reviewed 
in hematopoetic cell lines, many of them are present in leukocytes [37]. Next, a series of 
interactions of ATP and ADP with P2Y receptors on leukocytes were described, during 
vascular injury [38]. The type of P2 receptors playing a role in the currently observed effects 
on ROS production can differ among the type of NpnN tested, the cell type and the stimulus. 
The use of inhibitors like suramin, a P2 purinergic antagonist, α,β-methylene ATP, a P2X1 
inhibitor or other selective antagonists should elucidate this in the future. 
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Data on the effects of NpnN on leukocytes had been, up to now, limited to evaluation of the 
effect of some ApnA in neutrophils. It was found that Ap3A and Ap4A are able to prime the 
respiratory burst if followed by further fMLP stimulation in isolated neutrophils and this 
effect was Ca2+-dependent with NpnN concentrations above 50 µM. The priming effects 
appeared to be maximal when the ApnA were added 1 minute before fMLP and at 600-800 
µM [39]. The same group also found that ApnA (n = 3 – 6) delayed neutrophil apoptosis 
[40,41]. They also suggested that neutrophils express P2 receptors with different binding 
affinities to mononucleotides and dinucleotides [42]. Vartanian et al. found that interferons 
induce an accumulation of Ap3A in both a monocytic and a granulocytic human cell line due 
to an accumulation of the enzyme tryptophanyl-tRNA synthethase [43]. 
According to the standardized protocol for in vitro testing of uremic retention solutes 
developed by European uremic toxin workgroup (EUTox), the NpnN were tested at their 
highest estimated uremic concentration [30]. Considering the still limited available data on 
concentrations of NpnN in CKD, the NpnN concentration was based upon the release of ApnA 
by thrombocytes from hemodialysis patients [17]. NpnN are released by endothelial cells and 
platelets, which are both cell types playing a role in atherogenesis. Hence, it is likely that 
intravascularly leukocytes are locally exposed to similar NpnN concentrations especially if the 
producing cells are activated, as is the case for thrombocytes and endothelium in uremia [44]. 
The present data were obtained by performing acute experiments, with an exposure time of 
only 10 minutes. In vivo, the chronic exposure in CKD is however continuous, especially in 
atherosclerotic lesions, which contain macrophages, lymphocytes as well as thrombocytes, 
and thus the damaging impact is conceivably more persistent [26]. Of note, another possibility 
that should be considered is that the damaging effect of NpnN in vivo is attenuated by 
compensatory, regulatory and/or repairing mechanisms. Although such mechanisms certainly 
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are at play, it should be taken into account that the net in vivo result of these interactions still 
essentially is pro-inflammatory. 
The definition/specification of NpnN as uremic retention solutes is mainly based on the 
following observations; NpnN are endogeneous compounds with a strong impact on 
physiologic and pathophysiologic processes in the cardiovascular system [21,22,45]; NpnN 
are released by different cell types involved in atherosclerosis, the major cause of death in 
CKD (e.g. thrombocytes, endothelial cells) [15,18]; platelets from hemodialysis patients have 
an increased intracellular ApnA concentration and an increased release [17]; Up4A plasma 
concentration is increased in juvenile hypertensives versus normotensives and Up4A is 
described to affect glomerular filtration rate [22,45]. Uremic plasma concentrations in se have 
however rarely been reported. The quantification of NpnN in CKD (stage 2-5) and in uremic 
patients before and after hemodialysis is currently under investigation in different ongoing 
studies. Based upon the increased release of ApnA from platelets from hemodialysis patients 
[17], local concentrations of NpnN were calculated to rise up to 100 µM. 
Based on their molecular weight ranging from 800 to 1200 Dalton, the NpnN are classified as 
middle molecules. In addition, dinucleosides were shown to be protein bound [13]. Because 
of their physico-chemical characteristics NpnN are expected to be difficult to remove by 
dialysis, bringing along the need for more advanced removal strategies such as on line 
hemodiafiltration, adsorption and/or pharmaceutical interventions in function of the involved 
patho-physiological mechanism [10,12]. 
In conclusion, this study describes for the first time the effect of a series of NpnN on 
leukocyte oxidative burst activity in relation to uremia. Depending on the length of the 
phosphate chain, the type of nucleoside and the type of leukocyte, a different impact on the 
oxidative burst activity at baseline and after stimulation was observed. In general these data, 
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especially showing a pro-inflammatory effect, suggest that NpnN are likely to be involved in 
the development of atherosclerosis, probably in the early stages of CKD. 
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Figure legends 
Figure 1. Molecular structure of Np4N: Ap4A (A), Ap4G (B), Gp4G (C) and Up4A (D) 
Figure 2. Effect of the ApnA (n = 3-6) on the oxidative burst activity of monocytes, 
granulocytes and lymphocytes at baseline (A), after fMLP stimulation (B) and PMA 
stimulation (C). Data are expressed as the percentage rhodamine positive cells (%) at baseline 
and for the fMLP stimulus and as the mean fluorescence intensity (MFI) for the PMA 
stimulus. * P < 0.05, ** P < 0.01 versus saline; n = 8 
Figure 3. Effect of the Np4N on the oxidative burst activity of monocytes, granulocytes and 
lymphocytes at baseline (A), after fMLP stimulation (B) and PMA stimulation (C). Data are 
expressed as the percentage rhodamine positive cells (%) at baseline and for the fMLP 
stimulus and as the mean fluorescence intensity (MFI) for the PMA stimulus. * P < 0.05 
versus saline; n = 6 
 
 
 
 
